4 news items
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
.1 These data were presented as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
LEGN
22 Apr 24
.
3 American Cancer Society. "What is Multiple Myeloma?". Available
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
LEGN
5 Apr 24
.
3 American Cancer Society. "What is Multiple Myeloma?". Available
- Prev
- 1
- Next